A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 59, Issue 230, 1999, Pages 32-35

  Eda, Shinichi ^a   Kaufmann, Jörg ^a   Molwitz, Markus ^a   Vorberg, Ewald ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; MICROSPHERE; MONOCLONAL ANTIBODY;

CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; TURBIDIMETRY; ARTICLE; BLOOD; CLINICAL CHEMISTRY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; IMMUNOLOGY; METHODOLOGY; PHOTOMETRY; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMISTRY, CLINICAL; CORONARY DISEASE; HUMANS; MICROSPHERES; NEPHELOMETRY AND TURBIDIMETRY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0032617767     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519909168324     Document Type: Conference Paper

References (9)

1. Pepys MB, Baltz MC, Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A Protein, Adv Immunol, 1983; 34:141-212.
2. Schumann G, Dati F. Vorläufige Referenzbereiche für 14 Proteins im Serum (für Erwachsene) nach Standardisierung immunochemischer Methoden unter Bezug auf das internationale Referenzmaterial CRM 470, Lab Med, 1995; 19:401-403.
3. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A, The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina, N Engl J Med, 1994; 331:417-424.
4. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, Production of C-reactive protein and risk of coronary events in stable and unstable angina, Lancet, 1997; 349: 462-466.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, 1997; 336:973-979.
6. Price CP, Trull AK, Berry D, Gormann EG, Development and validation of a particle enhanced turbidimetric immunoassay for C-reactive protein, J Immunol Methods, 1987, 99:205-211.
7. Lammers M, Bienvenu J, Monneret G, Borque de Larrea L, Gaona N, Schumann G, Stevens WJ, Van Campenhout C, Evaluation of an improved immunonephelometric assay for C-reactive protein, Clin Chem, 1996; 42:S165 (Abstract).
8. Eda S, Kaufmann J, Roos W, Pohl S, Development of a new microparticle enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range, J Clin Lab Anal, 1998; 12:137-144.
9. Schwartz MW, Schifreen RS, Gorman E, Tuhy PM, Bienvenu J, Warkentin DL, Development and performance of a fully automated method for assay of C-reactive protein in the aca discrete clinical analyser, Clin Chem, 1988;34: 1646-164.